[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334638-105":59,"doc-detail-334638-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dihydroartemisinin-a-potential-ptgs1-inhibitor-potentiated-cisplatin-induced-cell-death-in-non-small-cell-lung-cancer-through-activating-ros-mediated-multiple-signaling-pathways-original-research","Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways - Original Research","","Dihydroartemisinin (DHA) enhances cisplatin anti-tumor activity in non-small cell lung cancer (NSCLC) by triggering reactive oxygen species (ROS)-mediated endoplasmic reticulum (ER) stress and activating JNK and p38 MAPK pathways in vitro and in vivo. DHA suppresses PTGS1 expression, leading to increased ROS production. PTGS1 knockdown further sensitizes DHA-induced cell death via elevated ROS, ER-stress signaling, and JNK/p38 MAPK activation. Results support combined DHA-cisplatin therapy for selected NSCLC patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dihydroartemisinin-a-potential-ptgs1-inhibitor-potentiated-cisplatin-induced-cell-death-in-non-small-cell-lung-cancer-through-activating-ros-mediated-multiple-signaling-pathways-original-research/334638/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dihydroartemisinin-a-potential-ptgs1-inhibitor-potentiated-cisplatin-induced-cell-death-in-non-small-cell-lung-cancer-through-activating-ros-mediated-multiple-signaling-pathways-original-research/334638.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does DHA play in NSCLC treatment with cisplatin?","Question",{"text":113,"@type":114},"DHA potentiates cisplatin’s anti-tumor effects in NSCLC cells. It does this by increasing ROS and activating multiple stress and signaling pathways in vitro and in vivo.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does DHA increase ROS production according to the study?",{"text":118,"@type":114},"DHA inhibits prostaglandin G/H synthase 1 (PTGS1) expression. Reduced PTGS1 expression results in enhanced ROS production.",{"name":120,"@type":111,"acceptedAnswer":121},"What happens when PTGS1 is silenced in DHA-treated cells?",{"text":122,"@type":114},"PTGS1 silencing sensitizes DHA-induced cell death. It increases ROS production and activates ER-stress, JNK, and p38 MAPK signaling pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},334638,1790014583,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Neoplasia 51 (2024) 100991  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>Dihydroartemisinin, a potential PTGS1 inhibitor, potentiatedcisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways |  | |\n| --- | --- | --- |\n| Lianli Nia, b, c, 1, Xinping Zhub, 1, Qi Zhao a, b, 1, Yiwei Shen b, Lu Tao b, Ji Zhang b, Han Lin b, Weishan Zhugeb, Young-Chang Cho c, ***, Ri Cuia, b, **, Wangyu Zhu a, b, *\u003Cbr>a Cellular and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang 316020, China;\u003Cbr>b Cancer and Anticancer Drug Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; c Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, South Korea |  |  |\n| A R T I C L E I N F O\u003Cbr>Keywords:\u003Cbr>Dihydroartemisinin (DHA) Cisplatin\u003Cbr>Endoplasmic reticulum (ER) stress Reactive oxygen species (ROS)\u003Cbr>Prostaglandin G/H synthase 1 (PTGS1) Mitogen-activated protein kinases (MAPK) | A B S T R A C T |  |\n|  | Dihydroartemisinin (DHA) exerts an anti-tumor effect in multiple cancers, however, the molecular mechanism of DHA and whether DHA facilitates the anti-tumor efficacy of cisplatin in non-small cell lung cancer (NSCLC) are unclear. Here, we found that DHA potentiated the anti-tumor effects of cisplatin in NSCLC cells by stimulating reactive oxygen species (ROS)-mediated endoplasmic reticulum (ER) stress, C-Jun-amino-terminal kinase (JNK) and p38 MAPK signaling pathways both in vitro and in vivo. Of note, we demonstrated for the first time that DHA inhibits prostaglandin G/H synthase 1 (PTGS1) expression, resulting in enhanced ROS production. Importantly, silencing PTGS1 sensitized DHA-induced cell death by increasing ROS production and activating ER-stress, JNK and p38 MAPK signaling pathways. In summary, our findings provided new experimental basis and therapeutic prospect for the combined therapy with DHA and cisplatin in some NSCLC patients. |  |\n\nIntroduction  \nLung cancer stands as one of the most prevalent malignant tumors, presenting significant health concerns characterized by its poor prognosis, high incidence, and mortality rates [1]. Non-small cell lung cancer (NSCLC) comprises a major subtype, representing approximately 85 % of all lung cancer cases [2]. Currently, chemotherapy remains the standard first-line treatment approach for advanced NSCLC [3,4].  \nHowever, considering the severe cytotoxicity and the emergence of drug resistance associated with the chemotherapeutic agents treating NSCLC, there is a compelling and imperative need to develop combined therapeutic strategy with strong anti-tumor effects and minor cytotoxicity.  \nResearch on natural compounds has attracted significant attention recently, especially regarding cancer treatment. In the last four decades, more than 30 % of drugs sanctioned by the Food and Drug Administration (FDA) have originated directly from natural compounds [5].  \nAbbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ATF4, Transcription factor 4; BC, Betweenness centrality; BP, Biological process; CC, Cellular component; CC, Closeness centrality; CI, Combination index; COX, Cyclooxygenase; DC, Degree centrality; DCFH-DA, 2′, 7′-dichlorodihydrofluorescin diacetate; DHA, Dihydroartemisinin; DMSO, Dimethylsulfoxide; EC, Eigenvector centrality; eIF2α, Eukaryotic initiation factor 2α; ER, Endoplasmic reticulum; GO, Gene ontology; H&E, Hematoxylin and eosin; JNK, C-Jun-amino-terminal kinase; LAC, Local average onnectivity-based method; MDA, Malondialdehyde; MF, Molecular function; MPO, Myeloperoxidase; MTT, 3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide; NAC, N-acetyl-L-cyste","cbCaids3hBAUzziE","https://ap.wps.com/l/cbCaids3hBAUzziE","pdf",7590486,15,"English","# Introduction\n## Background on lung cancer and NSCLC\n## Need for improved combination therapy\n## Natural compounds in cancer research\n# Study focus and key molecular targets","[{\"question\":\"What role does DHA play in NSCLC treatment with cisplatin?\",\"answer\":\"DHA potentiates cisplatin’s anti-tumor effects in NSCLC cells. It does this by increasing ROS and activating multiple stress and signaling pathways in vitro and in vivo.\"},{\"question\":\"How does DHA increase ROS production according to the study?\",\"answer\":\"DHA inhibits prostaglandin G/H synthase 1 (PTGS1) expression. Reduced PTGS1 expression results in enhanced ROS production.\"},{\"question\":\"What happens when PTGS1 is silenced in DHA-treated cells?\",\"answer\":\"PTGS1 silencing sensitizes DHA-induced cell death. It increases ROS production and activates ER-stress, JNK, and p38 MAPK signaling pathways.\"}]","Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways - Original Research | PDF",1790007608,38]